abemaciclib
-
April 6, 2022
Essential Breast Cancer Treatment Trends in 2022: Webinar Highlights
Sarah StanleyWomen with breast cancer often face an overwhelming amount of information to sort through and decisions to make. Whether newly diagnosed or starting a next step in treatment, they may wonder: What does the latest research say about my type of breast cancer? Should I enroll in a clinical trial? How do I know if I’m receiving my best-possible treatment? Every day, Cancer Commons… Read more »
-
May 31, 2017
The Trouble With KRAS
Emma Shtivelman, PhDMutations in the gene that encodes the KRAS protein are frequently encountered in various human cancers. They are found in about 30% of non-small cell lung cancers (NSCLCs), making KRAS the single most common gene mutated in this cancer. The rate of KRAS mutations in other cancers, such as pancreatic or colorectal, is even higher. A mutant KRAS protein that is always in the… Read more »
-
January 17, 2017
In Metastatic Breast Cancer Treatment, Not All CDK Inhibitors Are Equal
Emma Shtivelman, PhDDoctors prescribe drugs known as CDK inhibitors to treat some women with estrogen-receptor-positive (ER+) metastatic breast cancer. Research into these drugs is ongoing, and new, promising CDK inhibitor options are on the horizon. Here, I address the current outlook for CDK inhibitors in ER+ breast cancer. First, some background: ER+ breast cancers comprise about 70% of all breast cancers. The name reflects the fact… Read more »